Uncategorized Archives - Page 12 of 87 - PsychedelicNewsWire (PNW)

WednesdayFeb 23, 2022 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academics In a recent interview, company CEO Josh Bartch emphasized the need for consistent messaging to push the adoption of psychedelics among the medical community, and help assuage concerns of patients who may be wary of psychedelic treatments…

TuesdayFeb 22, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023 Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available 83% of Americans living with these conditions are open to trying out alternative treatments Delic seeks to capitalize on this growing demand for psychedelic alternatives, coupled with ongoing legislative and regulatory changes to grow its brand and increase value for its shareholders While the psychedelics industry might be in its early stages, its…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

FridayFeb 11, 2022 9:15 am

Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28 Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystem The laboratory focuses on extraction optimization, analytical testing, and chemical product and process development and is likely to continue supporting the cannabis industry with the latest technology and services as the cannabis market and cannabis extraction spaces mature Delic Holdings (CSE: DELC) (OTCQB: DELCF) recently announced that Dr. Markus Roggen – the President and Chief Science Officer of Delic Labs, a federally licensed cannabis…

TuesdayFeb 08, 2022 12:05 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation…

ThursdayFeb 03, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Wellness Clinics’ Reach to Communities Where Access to Life-Changing Mental Health Treatments is Limited

Tens of millions of Americans live in areas where mental health providers are scarce Delic is working on making psychedelic-based treatments more accessible and affordable In 2021, the company acquired Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers, becoming the owner and operator of the largest chain of wellness clinics administering ketamine treatments in the U.S. A May 2021 CNBC article exploring the cost and accessibility of mental health care in the United States noted that the number of Americans experiencing depression and anxiety had increased – a total of 42% of U.S. adults had reported symptoms, up from 11%…

WednesdayFeb 02, 2022 12:39 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compound Mydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwide The LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug products and related services to physicians, clinics and hospitals in Canada for psychotherapy Health Canada announced earlier this month that the government has amended its medicinal regulations to allow psilocybin and MDMA prescriptions…

MondayJan 31, 2022 1:04 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics. Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow. Enrollment for the study begins early this year (https://ibn.fm/XTXAe). “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized